[CAS NO. 1046045-61-7] FGH10019
PRODUCTS SPECIFICATIONS [1046045-61-7]
DESCRIPTION [1046045-61-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 373.49 |
| Molecular Formula | C18H19N3O2S2 |
| SMILES | CS(=O)(NC1=CC=C(C2=CSC(C3=CC(CCC)=NC=C3)=N2)C=C1)=O |
1 Publications Citing Use of MCE
Summary
FGH10019 is a novel sterol regulatory element-binding protein ( SREBP ) inhibitor with IC 50 of 1 μM.
IC50 & Target
IC50: 1 μM (SREBP)
In Vitro
Treatment of the CHO-K1 cells with analog FGH10019 decreases the percentage of the mature form of SREBP-2 (68 kDa) at lower concentrations than treatment with fatostatin. Densitometric analysis of the gels indicates that the IC 50 of analog FGH10019 is approximately 1 μM, which is 5-10 times lower than the IC 50 of fatostatin (appr 10 μM) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
FGH10019-treated chow is fed at a dose rate calculated to provide about 0.7 mg analog FGH10019 per day, at about 23 mg/kg body weight, to 5-wk-old male ob/ob mice weighing an average of appr 30 g. After 8 wk on the analog 24-treated chow, the mice gain 8-9 % less weight than control mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 38 mg/mL ( 101.74 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6774 mL | 13.3872 mL | 26.7745 mL |
| 5 mM | 0.5355 mL | 2.6774 mL | 5.3549 mL |
| 10 mM | 0.2677 mL | 1.3387 mL | 2.6774 mL |